Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.
We have investigated the interaction of azapropazone with phenytoin in five healthy volunteers. From steady‐state plasma phenytoin concentrations of about 17 mumol/l there was at least a two‐fold increase following the introduction of azapropazone. The main mechanism of the interaction was a decrease in phenytoin clearance, attributable to competitive inhibition by azapropazone of phenytoin p‐hydroxylation. Protein‐binding of phenytoin in the plasma (as assessed by salivary phenytoin concentrations) was significantly reduced from 92 to 90% by azapropazone and similar changes occurred in in vitro studies of [3H]‐ phenytoin protein binding. 1983 The British Pharmacological Society